Communiqués de presse
InnaVirVax announces the launch of the first clinical trial on VAC-3S, a novel immunotherapy for the treatment of HIV-1 infections
2012/03/06
This Phase I/IIa trial aims to evaluate the safety and immunogenicity of VAC-3S in patients infected with HIV-1 receiving antiretroviral therapy The first patients have been enrolled in two AP-HP Paris Hospitals This trial is supported by a grant from the “OSEO” French Innovation Agency
Latest News
